Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 1;27(17):4696-4699.
doi: 10.1158/1078-0432.CCR-21-0641. Epub 2021 Jun 2.

Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY)

Judy C Boughey  1 , Vera J Suman  2 , Jia Yu  3 , Katelyn Santo  2 , Jason P Sinnwell  2 , Jodi M Carter  4 , Krishna R Kalari  2 , Xiaojia Tang  2 , Sarah A McLaughlin  5 , Alvaro Moreno-Aspitia  6 , Donald W Northfelt  7 , Richard J Gray  8 , Katie N Hunt  9 , Amy Lynn Conners  9 , James N Ingle  10 , Ann Moyer  4 , Richard Weinshilboum  3 , John A Copland 3rd  11 , Liewei Wang  3 , Matthew P Goetz  12
Affiliations

Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY)

Judy C Boughey et al. Clin Cancer Res. .

Abstract

Purpose: Patient-derived xenografts (PDX) are a research tool for studying cancer biology and drug response phenotypes. While engraftment rates are higher for tumors with more aggressive characteristics, it is uncertain whether engraftment is prognostic for cancer recurrence.

Patients and methods: In a prospective study of patients with breast cancer treated with neoadjuvant chemotherapy (NAC) with taxane ± trastuzumab followed by anthracycline-based chemotherapy, we report the association between breast cancer events and PDX engraftment using tumors derived from treatment naïve (pre-NAC biopsies from 113 patients) and treatment resistant (post-NAC at surgery from 34 patients). Gray test was used to assess whether the cumulative incidence of a breast cancer event differs with respect to either pre-NAC PDX engraftment or post-NAC PDX engraftment.

Results: With a median follow-up of 5.7 years, the cumulative incidence of breast cancer relapse did not differ significantly according to pre-NAC PDX engraftment (5-year rate: 13.6% vs. 13.4%; P = 0.89). However, the incidence of a breast event was greater for patients with post-NAC PDX engraftment (5-year rate: 50.0% vs. 19.6%), but this did not achieve significance (P = 0.11).

Conclusions: In treatment-naïve breast cancer receiving standard NAC, PDX engraftment was not prognostic for breast cancer recurrence. Further study is needed to establish whether PDX engraftment in the treatment-resistant setting is prognostic for cancer recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Statement: The authors have no relevant conflicts of interest to declare.

Figures

Figure 1:
Figure 1:
Time to breast cancer event according to PDX engraftment in A) all patients prior to neoadjuvant chemotherapy; B) in triple negative breast cancer patients prior to neoadjuvant chemotherapy; and all patients prior to neoadjuvant chemotherapy according to type of mouse strain C) NSG and D) NOD-SCID
Figure 2:
Figure 2:
Time to breast cancer event according to PDX engraftment in patients with residual disease after neoadjuvant chemotherapy
See this image and copyright information in PMC

References

    1. Weroha SJ, Becker MA, Enderica-Gonzalez S, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res 2014;20:1288–97. - PMC - PubMed
    1. Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014;4:998–1013. - PMC - PubMed
    1. DeRose YS, Wang G, Lin YC, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011;17:1514–20. - PMC - PubMed
    1. Goetz MP, Kalari KR, Suman VJ, et al. Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. J Natl Cancer Inst 2017;109. - PMC - PubMed
    1. Yu J, Qin B, Moyer AM, et al. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Res 2017;19:130. - PMC - PubMed

Publication types